Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials

Expert Opinion on Biological Therapy

Volumn 16, Issue 10, 2016, Pages 1225-1238

  Medina Rosas, Jorge ^a   Al Rayes, Hanan ^a   Moustafa, Ahmed T ^a   Touma, Zahi ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

biological therapy; clinical trials; immunosuppressive agents; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ANIFROLUMAB; ATACICEPT; AUTOANTIBODY; BELIMUMAB; BIOLOGICAL PRODUCT; BLISIBIMOD; CYCLOPHOSPHAMIDE; CYTOKINE; EDRATIDE; EPRATUZUMAB; FORIGERIMOD; GLUCOCORTICOID; INTERFERON; MYCOPHENOLATE MOFETIL; OCRELIZUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; SIRUKUMAB; TABALUMAB; TOCILIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

B LYMPHOCYTE; BIOLOGICAL THERAPY; BRITISH ISLES LUPUS ASSESSMENT GROUP INDEX; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL (TOPIC); CUTANEOUS LUPUS ERYTHEMATOSUS DISEASE AREA AND SEVERITY INDEX; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ETHNICITY; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PROSPECTIVE STUDY; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAFETY OF ESTROGEN IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT TRIAL; SAMPLE SIZE; SLEDAI; STUDY DESIGN; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT RESPONSE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCEDURES; TRENDS;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84985995078     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1214263     Document Type: Review

References (94)

1. B.Dema, N.Charles Advances in mechanisms of systemic lupus erythematosus. Discov Med. 2014 May;17(95):247–255.• This article summarizes the recent developments in the pathogenic mechanisms of systemic lupus erythematosus and its importance for potential new treatment strategies.
2. D.Squatrito, G.Emmi, E.Silvestri, et al. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus:from bench to bedside. Auto Immun Highlights. 2014 Sep;5(2):33–45. doi:10.1007/s13317-014-0058-y.
3. Z.Rosman, Y.Shoenfeld, G.Zandman-Goddard. Biologic therapy for autoimmune diseases:an update. BMC Med. 2013 04/04 06/14/received 01/11/accepted; 11:88–88. doi:10.1186/1741-7015-11-88.
4. E.G.Boyce, B.E.Fusco. Belimumab:review of use in systemic lupus erythematosus. Clin Ther. 2012 May;34(5):1006–1022. doi:10.1016/j.clinthera.2012.02.028.
5. F.A.Houssiau, A.Doria. Targeting BAFF/BLyS in lupus:is the glass half-full or half-empty? Ann Rheum Dis. 2016 Feb;75(2):321–322. doi:10.1136/annrheumdis-2015-208312.• This editorial explains the potential reasons for the failure of the tabalumab trials.
6. Z.Touma, D.D.Gladman, M.B.Urowitz. Clinical measures, metrics, and indices. In:D.J.Wallace, B.H.Hahn, editors. Dubois’ lupus erythematosus and related syndromes. 8th ed. Philadelphia(PA):Elsevier/Saunders; 2013. p. 563–581.
7. C.Bombardier, D.D.Gladman, M.B.Urowitz, et al. Derivation of the SLEDAI:a disease activity index for lupus patients. Arthritis Rheum 1992;35. doi:10.1002/art.1780350606.
8. M.Petri, M.Y.Kim, K.C.Kalunian, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550–2558.
9. D.P.Symmons, J.S.Coppock, P.A.Bacon, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937.
10. D.A.Isenberg, A.Rahman, E.Allen, et al. BILAG 2004. development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 Jul;44(7):902–906. doi:10.1093/rheumatology/keh624.
11. D.J.Wallace, W.Stohl, R.A.Furie, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168–1178.
12. R.A.Furie, M.A.Petri, D.J.Wallace, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143–1151. doi:10.1002/art.24698.• Article describing the SRI, a composite index for assessing clinical responders in lupus clinical trials.
13. D.Wallace, V.Strand, R.Furie, et al. Evaluation of treatment success in systemic lupus erythematosus clinical trials:development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S885.
14. D.J.Wallace, K.Kalunian, M.A.Petri, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus:results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183–190. doi:10.1136/annrheumdis-2012-202760.• Article describing the BICLA, a composite index for assessing clinical responders in lupus clinical trials.
15. D.D.Gladman, D.Ibanez, M.B.Urowitz. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288–291.
16. V.C.Kyttaris. New treatments for systemic lupus erythematosus. In:G.T.Tsokos, editor. Systemic lupus erythematosus basic, applied and clinical aspects. London(UK):Academic Press; 2016. p. 551–557.
17. A.Leone, S.Sciascia, A.Kamal, et al. Biologicals for the treatment of systemic lupus erythematosus:current status and emerging therapies. Expert Rev Clin Immunol. 2015 Jan;11(1):109–116. doi:10.1586/1744666X.2015.994508.•• This review summarizes the immunological target and the most recent clinical trials of recent biological drugs developed for the treatment of systemic lupus erythematosus.
18. T.A.Gottschalk, E.Tsantikos, M.L.Hibbs. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol. 2015;6:550. doi:10.3389/fimmu.2015.00550.
19. N.Jordan, P.M.Lutalo, D.P.D’Cruz. Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus. Immunotherapy. 2015;7(3):255–270. doi:10.2217/imt.14.118.
20. L.Zhao, Y.Ye, X.Zhang. B cells biology in systemic lupus erythematosus-from bench to bedside. Science China Life Sciences. 2015 Nov;58(11):1111–1125. doi:10.1007/s11427-015-4953-x.
21. J.T.Merrill, C.M.Neuwelt, D.J.Wallace, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus:the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan;62(1):222–233. doi:10.1002/art.27233.
22. B.H.Rovin, R.Furie, K.Latinis, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis:the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012 Apr;64(4):1215–1226. doi:10.1002/art.34359.
23. S.V.Navarra, R.M.Guzman, A.E.Gallacher, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus:a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721–731.
24. R.Furie, M.Petri, O.Zamani, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec;63(12):3918–3930. doi:10.1002/art.30613.
25. R.F.van Vollenhoven, M.A.Petri, R.Cervera, et al. Belimumab in the treatment of systemic lupus erythematosus:high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343–1349. doi:10.1136/annrheumdis-2011-200937.
26. M.A.Dooley, F.Houssiau, C.Aranow, et al. Effect of belimumab treatment on renal outcomes:results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013 Jan;22(1):63–72. doi:10.1177/0961203312465781.
27. W.Stohl, J.T.Merrill, R.J.Looney, et al. Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623):results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015;17:215. doi:10.1186/s13075-015-0741-z.
28. R.A.Furie, G.Leon, M.Thomas, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015 Sep;74(9):1667–1675. doi:10.1136/annrheumdis-2013-205144.
29. A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus (CHABLIS-SC1). ClinicalTrials.gov Identifier:NCT01395745. Bethesda (MD):National Library of Medicine (US); 2011.
30. CHABLIS-SC2:A study of the efficacy and safety of subcutaneous blisibimod in subjects with systemic lupus erythematosus with or without nephritis. ClinicalTrials.gov Identifier:NCT02074020. Bethesda (MD):National Library of Medicine (US); 2014.
31. CHABLIS7.5:A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis. Bethesda (MD):National Library of Medicine (US); 2015.
32. W.Stohl. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr;18(4):473–489. doi:10.1517/14728222.2014.888415.• Review summarizing the components of the BAFF/APRIL axis and potential targets for biological drugs.
33. D.A.Isenberg, M.Petri, K.Kalunian, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus:results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb;75(2):323–331. doi:10.1136/annrheumdis-2015-207653.
34. J.T.Merrill, R.F.van Vollenhoven, J.P.Buyon, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus:results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb;75(2):332–340. doi:10.1136/annrheumdis-2015-207654.
35. E.Robak, T.Robak. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Current Drug Targets. 2009 Jan;10(1):26–37.
36. T.Dorner, D.M.Goldenberg. Targeting CD22 as a strategy for treating systemic autoimmune diseases. Ther Clin Risk Manag. 2007 Oct;3(5):953–959.
37. H.Al Rayes, Z.Touma. Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2014;8:2303–2310. doi:10.2147/DDDT.S49778.
38. T.Dorner, J.Kaufmann, W.A.Wegener, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8(3):R74. doi:10.1186/ar1942.
39. D.J.Wallace, C.Gordon, V.Strand, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus:results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford). 2013 Jul;52(7):1313–1322. doi:10.1093/rheumatology/ket129.
40. V.Strand, M.Petri, K.Kalunian, et al. Epratuzumab for patients with moderate to severe flaring SLE:health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. Rheumatology (Oxford, England). 2014 Mar;53(3):502–511. doi:10.1093/rheumatology/ket378.
41. D.J.Wallace, K.Hobbs, M.E.Clowse, et al. Long-term safety and efficacy of epratuzumab in the treatment of moderate-to- severe systemic lupus erythematosus:results from an open-label extension study. Arthritis Care Res (Hoboken). 2016 Apr;68(4):534–543. doi:10.1002/acr.22694.
42. M.E.B.Clowse, D.J.Wallace, R.Furie, et al. Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus:results from two phase 3 randomized, placebo-controlled trials [abstract]. Arthritis Rheumatol. 2015;67(suppl 10):2015.
43. M.C.Genovese, J.L.Kaine, M.B.Lowenstein, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis:a phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008 Sep;58(9):2652–2661. doi:10.1002/art.23732.
44. E.F.Mysler, A.J.Spindler, R.Guzman, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis:results from a randomized, double-blind, phase iii study. Arthritis Rheum. 2013;65(9):2368–2379. doi:10.1002/art.38037.
45. E.Cogollo, M.A.Silva, D.Isenberg. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331–1339. doi:10.2147/DDDT.S71276.
46. M.Dall’Era, E.Chakravarty, D.Wallace, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus:results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec;56(12):4142–4150. doi:10.1002/art.23047.
47. E.M.Ginzler, S.Wax, A.Rajeswaran, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis:results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33. doi:10.1186/ar3738.
48. D.Isenberg, C.Gordon, D.Licu, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE):52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. 2015 Nov;74(11):2006–2015. doi:10.1136/annrheumdis-2013-205067.
49. Z.Touma, D.D.Gladman, D.Ibanez, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011 Feb;38(2):275–284. doi:10.3899/jrheum.100724.
50. Efficacy and safety of atacicept in systemic lupus erythematosus (ADDRESS II). ClinicalTrials.gov Identifier:NCT01972568. Bethesda (MD):National Library of Medicine (US); 2013.
51. J.T.Merrill, R.Burgos-Vargas, R.Westhovens, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus:results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct;62(10):3077–3087. doi:10.1002/art.27601.
52. R.Furie, K.Nicholls, T.T.Cheng, et al. Efficacy and safety of abatacept in lupus nephritis:a twelve-month, randomized, double-blind study. Arthritis Rheumatol (Hoboken, NJ). 2014 Feb;66(2):379–389. doi:10.1002/art.38260.
53. D.Wofsy, J.L.Hillson, B.Diamond. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials. Arthritis Rheum. 2013 Jun;65(6):1586–1591. doi:10.1002/art.37940.• Article explaining how the choice of a trial’s primary end point influences its ability to detect clinical benefit in lupus nephritis.
54. ACCESS Trial group. Treatment of lupus nephritis with abatacept:the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol (Hoboken, NJ). 2014 Nov;66(11):3096–3104.
55. Z.M.Sthoeger, A.Sharabi, Y.Molad, et al. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide):immunomodulation of gene expression. J Autoimmun. 2009 Aug;33(1):77–82. doi:10.1016/j.jaut.2009.03.009.
56. M.B.Urowitz, D.A.Isenberg, D.J.Wallace. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus:results of phase II study. Lupus Sci Med. 2015;2(1):e000104. doi:10.1136/lupus-2015-000104.
57. N.Schall, S.Muller. Resetting the autoreactive immune system with a therapeutic peptide in lupus. Lupus. 2015 Apr;24(4–5):412–418. doi:10.1177/0961203314556138.
58. S.Muller, F.Monneaux, N.Schall, et al. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus:results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873–3883. doi:10.1002/art.24027.
59. R.Zimmer, H.R.Scherbarth, O.L.Rillo, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus:a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis. 2013 Nov;72(11):1830–1835. doi:10.1136/annrheumdis-2012-202460.
60. A 52-week, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of a 200-mcg dose of IPP-201101 plus standard of care in patients with systemic lupus erythematosus (LUPUZOR). Bethesda (MD):National Library of Medicine (US); 2015.
61. G.G.Illei, Y.Shirota, C.H.Yarboro, et al. Tocilizumab in systemic lupus erythematosus:data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 Feb;62(2):542–552. doi:10.1002/art.27221.
62. U.Thanarajasingam, T.B.Niewold. Sirukumab:a novel therapy for lupus nephritis? Expert Opin Investig Drugs. 2014 Oct;23(10):1449–1455. doi:10.1517/13543784.2014.950837.
63. Z.Xu, E.Bouman-Thio, C.Comisar, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011 Aug;72(2):270–281. doi:10.1111/j.1365-2125.2011.03964.x.
64. J.C.Szepietowski, S.Nilganuwong, A.Wozniacka, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013 Oct;65(10):2661–2671. doi:10.1002/art.38091.
65. B.Rovin, R.van Vollenhoven, C.Aranow, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol. 2016 Apr 25. [Epub ahead of print].
66. A.Mathian, M.Hie, F.Cohen-Aubart, et al. Targeting interferons in systemic lupus erythematosus:current and future prospects. Drugs. 2015 May;75(8):835–846. doi:10.1007/s40265-015-0394-x.
67. J.T.Merrill, D.J.Wallace, M.Petri, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon alpha monoclonal antibody, in systemic lupus erythematosus:a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905–1913. doi:10.1136/ard.2010.144485.
68. B.Zheng, X.Q.Yu, W.Greth, et al. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients. Br J Clin Pharmacol. 2016 May;81(5):918–928. doi:10.1111/bcp.12864.
69. M.Khamashta, J.T.Merrill, V.P.Werth, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus:a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Mar 23. [Epub ahead of print].
70. T.Takeuchi, Y.Tanaka A study to evaluate safety and tolerability of IV or SC dose of MEDI-545 in patients with systemic lupus erythematosus. ClinicalTrials.gov Identifier:NCT01031836. Bethesda (MD):National Library of Medicine (US); 2009.
71. J.M.McBride, J.Jiang, A.R.Abbas, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus:results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012 Nov;64(11):3666–3676. doi:10.1002/art.34632.
72. K.C.Kalunian, J.T.Merrill, R.Maciuca, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan;75(1):196–202. doi:10.1136/annrheumdis-2014-206090.
73. X.Guo, L.Wang, G.Illei, et al. Anifrolumab differentially suppresses peripheral biomarkers of systemic lupus erythematosus compared with placebo in a phase IIb trial [abstract]. Arthritis Rheumatol. 2015;67(suppl):10.
74. P.Brohawn, L.Santiago, M.Chris, et al. Target modulation of a type I interferon gene signature and pharmacokinetics of anifrolumab in a phase IIb study of patients with moderate to severe systemic lupus erythematosus [abstract]. Arthritis Rheumatol. 2015;67(suppl):10.
75. R.Furie, J.T.Merrill, V.P.Werth, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2015;67(Suppl):10.
76. A.S.Levey, P.E.de Jong, J.Coresh, et al. The definition, classification, and prognosis of chronic kidney disease:a KDIGO controversies conference report. Kidney Int. 2011 Jul;80(1):17–28. doi:10.1038/ki.2010.483.
77. Z.Touma, M.B.Urowitz. Systemic glucocorticoids. In:G.C.Tsokos, editor. Systemic lupus erythematosus. Harvard Medical School, Boston(MA):Elsevier; 2016.
78. Z.Touma, D.D.Gladman, M.B.Urowitz, et al. Mycophenolate mofetil for induction treatment of lupus nephritis:a systematic review and metaanalysis. J Rheumatol. 2011 Jan;38(1):69–78. doi:10.3899/jrheum.100130.
79. J.Albrecht, L.Taylor, J.A.Berlin, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index):an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894. doi:10.1111/j.0022-202X.2005.23889.x.
80. Z.Touma, D.D.Gladman, D.Ibanez, et al. SLEDAI-2K responder index 50 captures 50% improvement in disease activity over 10 years. Lupus. 2012 Oct;21(12):1305–1311. doi:10.1177/0961203312454344.
81. M.Dall’Era, M.G.Cisternas, D.E.Smilek, et al. Predictors of long-term renal outcome in lupus nephritis trials:lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305–1313. doi:10.1002/art.39026.
82. M.A.Dooley, C.Aranow, E.M.Ginzler. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004;13(11):857–860.
83. B.H.Hahn, M.A.McMahon, A.Wilkinson, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun;64(6):797–808. doi:10.1002/acr.21664.
84. E.M.Ginzler, M.A.Dooley, C.Aranow, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24;353(21):2219–2228.
85. G.B.Appel, G.Contreras, M.A.Dooley, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 May;20(5):1103–1112. doi:10.1681/ASN.2008101028.
86. J.Medina-Rosas, K.S.Yap, M.Anderson, et al. Utility of urinary protein creatinine ratio and protein content in a 24 hour-urine collection in lupus:systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2015 Dec 29. [Epub ahead of print].
87. D.J.Birmingham, G.Shidham, A.Perna, et al. Spot PC ratio estimates of 24-hour proteinuria are more unreliable in lupus nephritis than in other forms of chronic glomerular disease. Ann Rheum Dis. 2014 Feb;73(2):475–476.
88. J.Medina-Rosas, D.D.Gladman, J.Su, et al. Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. Arthritis Res Ther. 2015;17:296. doi:10.1186/s13075-015-0808-x.
89. D.Isenberg. Further thoughts about the ILLUMINATE studies of tabalumab in SLE. Ann Rheum Dis. 2016 Feb;75(2):e11. doi:10.1136/annrheumdis-2015-208709.
90. S.Hahn. Understanding noninferiority trials. Korean J Pediatr. 2012 Nov;55(11):403–407. doi:10.3345/kjp.2012.55.11.403.
91. Z.Touma, M.B.Urowitz, D.Ibanez, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014 Apr;41(4):688–697. doi:10.3899/jrheum.130005.
92. Z.Touma, D.D.Gladman, J.Su, et al. Time to recovery of individual lupus manifestations on standard of care treatment. Arthritis Rheum. 2015;67(suppl 10). Abstract
93. Z.Touma, D.D.Gladman, A.MacKinnon, et al. Development and assessment of users’ satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website. J Rheumatol. 2013 Jan;40(1):34–39. doi:10.3899/jrheum.120754.
94. M.C.Pike, L.Kelley. Data quality challenges in systemic lupus erythematosus trials:how can this be optimized? Curr Rheumatol Rep. 2012 Aug;14(4):324–333. doi:10.1007/s11926-012-0261-7.